相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma
Rachel Lubong Sabado et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Nonclassical Antigen-Processing Pathways Are Required for MHC Class II-Restricted Direct Tumor Recognition by NY-ESO-1-Specific CD4+ T Cells
Junko Matsuzaki et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity
Rachel Perret et al.
CANCER RESEARCH (2013)
Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide
Shingo Eikawa et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients
Shigehisa Kitano et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
Takemasa Tsuji et al.
CANCER IMMUNOLOGY RESEARCH (2013)
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions
Peggy J. de Vos van Steenwijk et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Paul Sabbatini et al.
CLINICAL CANCER RESEARCH (2012)
Virus-like particles induce robust human T-helper cell responses
Marion Braun et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients
Simone M. Goldinger et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells
Petra Baumgaertner et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype
Daniel Hirschhorn-Cymerman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Heat Shock Protein 90-Mediated Peptide-Selective Presentation of Cytosolic Tumor Antigen for Direct Recognition of Tumors by CD4+ T Cells
Takemasa Tsuji et al.
JOURNAL OF IMMUNOLOGY (2012)
The Present and Future of Peptide Vaccines for Cancer Single or Multiple, Long or Short, Alone or in Combination?
Craig L. Slingluff
CANCER JOURNAL (2011)
Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naive Prostate Cancer Patients
Julia Karbach et al.
CLINICAL CANCER RESEARCH (2011)
A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen
Kazuhiro Kakimi et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide® ISA-51: association with survival
Julia Karbach et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
Sergio A. Quezada et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Long Peptide Vaccination Can Lead to Lethality through CD4+ T Cell-Mediated Cytokine Storm
Hiroshi Kitamura et al.
JOURNAL OF IMMUNOLOGY (2010)
Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients
Yu Mizote et al.
VACCINE (2010)
Tumor Antigen-Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts
Camilla Jandus et al.
CANCER RESEARCH (2009)
Cancer/testis (CT) antigens: Potential targets for immunotherapy
Otavia L. Caballero et al.
CANCER SCIENCE (2009)
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia.
Gemma G. Kenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Induction of tumor-specific CD4+ and CD8+ T-Cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine
Marij J. P. Welters et al.
CLINICAL CANCER RESEARCH (2008)
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows lowtoxicity and robust immunogenicity
Gemma G. Kenter et al.
CLINICAL CANCER RESEARCH (2008)
Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation
Martijn S. Bijker et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines
Cornelis J. M. Melief et al.
NATURE REVIEWS CANCER (2008)
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity
Martijn S. Bijker et al.
JOURNAL OF IMMUNOLOGY (2007)
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
Danila Valmori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Development of TLR9 agonists for cancer therapy
Arthur M. Krieg
JOURNAL OF CLINICAL INVESTIGATION (2007)
High accumulation of T regulatory cells prevents the activation of immune responses in aged animals
Sanjay Sharma et al.
JOURNAL OF IMMUNOLOGY (2006)
Melan-A/MART-1-specific CD4 T cells in melanoma patients: Identification of new epitopes specific T cells by MHC class and ex vivo visualization of II Tetramers
Gilles Bioley et al.
JOURNAL OF IMMUNOLOGY (2006)
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site
Victor Appay et al.
JOURNAL OF IMMUNOLOGY (2006)
Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-α induction by CpG-A in plasmacytoid dendritic cells
M Kerkmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma
M Mandic et al.
JOURNAL OF IMMUNOLOGY (2005)
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
QY Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo
JN Blattman et al.
NATURE MEDICINE (2003)
Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs
S Gnjatic et al.
JOURNAL OF IMMUNOLOGY (2003)
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides
S Zwaveling et al.
JOURNAL OF IMMUNOLOGY (2002)
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele
S Gnjatic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
